ERBB2 and breast carcinoma: Importantly, due to their significant efficacy, CDK4/6 inhibitors are now recommended in the clinical practice, in the first-line or second-line setting in women with HR+, HER2- breast cancer, in combination with hormonal or targeted therapies [224].